Literature DB >> 26142329

Proinflammatory and proosteoclastogenic potential of peripheral blood mononuclear cells from Gaucher patients: Implication for bone pathology.

J M Mucci1, M F Cuello2, I Kisinovsky3, M Larroude4, M V Delpino5, P A Rozenfeld6.   

Abstract

Gaucher disease (GD) is caused by mutations in the GBA gene that confer a deficient level of activity of glucocerebrosidase (GCase). This deficiency leads to the accumulation of the glycolipid glucocerebroside in the lysosomes of cells of monocyte/macrophage system. Bone compromise in Gaucher disease patients is the most disabling aspect of the disease. However, pathophysiological aspects of skeletal alterations are still poorly understood. On the other hand it is well known that inflammation is a key player in GD pathology. In this work, we revealed increased levels of the proinflammatory CD14(+)CD16(+) monocyte subset and increased inflammatory cytokine production by monocytes and T cells in the circulation of GD patients. We showed increased levels of osteoclast precursors in PBMC from patients and a higher expression of RANKL in the surface of T cells. PBMC from patients presented higher osteoclast differentiation compared to healthy controls when cultured in the presence of M-CSF alone or in combination with RANKL. In vitro treatment with Velaglucerase reduced osteoclast levels to control levels. On the other hand THP-1 derived osteoclast precursors cultured in the presence of conditioned media from PBMC of GD patients presented higher differentiation to active osteoclasts. This induction involved TNF-α and RANKL.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone pathology; Gaucher disease; Glucocerebrosidase deficiency; Osteoclasts; Osteoimmunology

Mesh:

Substances:

Year:  2015        PMID: 26142329     DOI: 10.1016/j.bcmd.2015.05.009

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  10 in total

1.  Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1.

Authors:  Juliette Berger; Marie Vigan; Bruno Pereira; Thu Thuy Nguyen; Roseline Froissart; Nadia Belmatoug; Florence Dalbiès; Agathe Masseau; Christian Rose; Christine Serratrice; Yves-Marie Pers; Ivan Bertchansky; Fabrice Camou; Monia Bengherbia; Céline Bourgne; Catherine Caillaud; Magali Pettazzoni; Amina Berrahal; Jérôme Stirnemann; France Mentré; Marc G Berger
Journal:  Clin Pharmacokinet       Date:  2019-04       Impact factor: 6.447

2.  Osteocyte Alterations Induce Osteoclastogenesis in an In Vitro Model of Gaucher Disease.

Authors:  Constanza Bondar; Maximiliano Ormazabal; Andrea Crivaro; Malena Ferreyra-Compagnucci; María Victoria Delpino; Paula Adriana Rozenfeld; Juan Marcos Mucci
Journal:  Int J Mol Sci       Date:  2017-01-13       Impact factor: 5.923

3.  Circulating microparticles in acute diabetic Charcot foot exhibit a high content of inflammatory cytokines, and support monocyte-to-osteoclast cell induction.

Authors:  Jennifer Pasquier; Binitha Thomas; Jessica Hoarau-Véchot; Tala Odeh; Amal Robay; Omar Chidiac; Soha R Dargham; Rebal Turjoman; Anna Halama; Khalid Fakhro; Robert Menzies; Amin Jayyousi; Mahmoud Zirie; Jassim Al Suwaidi; Arash Rafii; Rayaz A Malik; Talal Talal; Charbel Abi Khalil
Journal:  Sci Rep       Date:  2017-11-27       Impact factor: 4.379

Review 4.  A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.

Authors:  Jérôme Stirnemann; Nadia Belmatoug; Fabrice Camou; Christine Serratrice; Roseline Froissart; Catherine Caillaud; Thierry Levade; Leonardo Astudillo; Jacques Serratrice; Anaïs Brassier; Christian Rose; Thierry Billette de Villemeur; Marc G Berger
Journal:  Int J Mol Sci       Date:  2017-02-17       Impact factor: 5.923

5.  Efficacy of pentosan polysulfate in in vitro models of lysosomal storage disorders: Fabry and Gaucher Disease.

Authors:  Andrea N Crivaro; Juan M Mucci; Constanza M Bondar; Maximiliano E Ormazabal; Romina Ceci; Calogera Simonaro; Paula A Rozenfeld
Journal:  PLoS One       Date:  2019-05-31       Impact factor: 3.240

6.  Gene expression profile in patients with Gaucher disease indicates activation of inflammatory processes.

Authors:  Agnieszka Ługowska; Katarzyna Hetmańczyk-Sawicka; Roksana Iwanicka-Nowicka; Anna Fogtman; Jarosław Cieśla; Joanna Karolina Purzycka-Olewiecka; Dominika Sitarska; Rafał Płoski; Mirella Filocamo; Susanna Lualdi; Małgorzata Bednarska-Makaruk; Marta Koblowska
Journal:  Sci Rep       Date:  2019-04-15       Impact factor: 4.379

Review 7.  What Are the Peripheral Blood Determinants for Increased Osteoclast Formation in the Various Inflammatory Diseases Associated With Bone Loss?

Authors:  Teun J de Vries; Ismail El Bakkali; Thomas Kamradt; Georg Schett; Ineke D C Jansen; Patrizia D'Amelio
Journal:  Front Immunol       Date:  2019-03-19       Impact factor: 7.561

8.  Liver involvement in patients with Gaucher disease types I and III.

Authors:  Rodrigo Tzovenos Starosta; Filippo Pinto E Vairo; Alícia Dorneles Dornelles; Suélen Porto Basgalupp; Marina Siebert; Maria Lúcia Alves Pedroso; Carlos Thadeu Schmidt Cerski; Mário Reis Álvares-da-Silva; Ida Vanessa Doederlein Schwartz
Journal:  Mol Genet Metab Rep       Date:  2020-01-07

9.  TRAP5b and RANKL/OPG Predict Bone Pathology in Patients with Gaucher Disease.

Authors:  Margarita Ivanova; Julia Dao; Lauren Noll; Jacqueline Fikry; Ozlem Goker-Alpan
Journal:  J Clin Med       Date:  2021-05-20       Impact factor: 4.241

10.  Effects of sphingolipids overload on red blood cell properties in Gaucher disease.

Authors:  Lucie Dupuis; Caroline Chipeaux; Emmanuelle Bourdelier; Suella Martino; Nelly Reihani; Nadia Belmatoug; Thierry Billette de Villemeur; Bénédicte Hivert; Fathi Moussa; Caroline Le Van Kim; Marine de Person; Mélanie Franco
Journal:  J Cell Mol Med       Date:  2020-08-07       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.